Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBITDA: 2019-2024

Historic EBITDA for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$85.7 million.

  • Foghorn Therapeutics' EBITDA rose 14.35% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year increase of 18.56%. This contributed to the annual value of -$85.7 million for FY2024, which is 10.08% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported EBITDA of -$85.7 million as of FY2024, which was up 10.08% from -$95.3 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' EBITDA registered a high of -$68.8 million during FY2020, and its lowest value of -$112.9 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$95.3 million (2023), whereas its average is -$97.9 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' EBITDA tumbled by 47.26% in 2021, and later increased by 15.59% in 2023.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' EBITDA stood at -$68.8 million in 2020, then tumbled by 47.26% to -$101.3 million in 2021, then declined by 11.38% to -$112.9 million in 2022, then increased by 15.59% to -$95.3 million in 2023, then climbed by 10.08% to -$85.7 million in 2024.